Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 60 X 250 mg |
|
83513 | 12427 |
|
Tablets 60 X 500 mg |
|
83514 | 12428 |
|
Tablets 60 X 1000 mg |
|
83515 | 12429 |
Related information
Dosage
See prescribing information for full details.
Indications
As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.As adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.As monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy.In the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Contra-Indications
Known hypersensitivity to levetiracetam, to other pyrrolidone derivatives, or to any other ingredient of the preparation.
